Immunovia`s blood-based IMMray™ biomarker array provides highly accurate diagnosis of non-small cell lung cancer in a new collaborative study
LUND, SWEDEN ― Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy. Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.The study included 100 serum samples - 50 NSCLC and 50 controls - and was performed to assess the technical performance of the IMMray™ platform in lung cancer. As a consequence of the